CSBR
Price
$8.61
Change
+$0.81 (+10.38%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
115.59M
54 days until earnings call
MREO
Price
$1.79
Change
+$0.08 (+4.68%)
Updated
Jul 17, 04:59 PM (EDT)
Capitalization
278.25M
82 days until earnings call
Interact to see
Advertisement

CSBR vs MREO

Header iconCSBR vs MREO Comparison
Open Charts CSBR vs MREOBanner chart's image
Champions Oncology
Price$8.61
Change+$0.81 (+10.38%)
Volume$2.79K
Capitalization115.59M
Mereo BioPharma Group
Price$1.79
Change+$0.08 (+4.68%)
Volume$17.65K
Capitalization278.25M
CSBR vs MREO Comparison Chart in %
Loading...
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CSBR vs. MREO commentary
Jul 18, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CSBR is a Buy and MREO is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 18, 2025
Stock price -- (CSBR: $7.80 vs. MREO: $1.75)
Brand notoriety: CSBR and MREO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CSBR: 48% vs. MREO: 118%
Market capitalization -- CSBR: $115.59M vs. MREO: $283.02M
CSBR [@Biotechnology] is valued at $115.59M. MREO’s [@Biotechnology] market capitalization is $283.02M. The market cap for tickers in the [@Biotechnology] industry ranges from $299.62B to $0. The average market capitalization across the [@Biotechnology] industry is $2.44B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CSBR’s FA Score shows that 1 FA rating(s) are green whileMREO’s FA Score has 1 green FA rating(s).

  • CSBR’s FA Score: 1 green, 4 red.
  • MREO’s FA Score: 1 green, 4 red.
According to our system of comparison, CSBR is a better buy in the long-term than MREO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CSBR’s TA Score shows that 6 TA indicator(s) are bullish while MREO’s TA Score has 5 bullish TA indicator(s).

  • CSBR’s TA Score: 6 bullish, 5 bearish.
  • MREO’s TA Score: 5 bullish, 5 bearish.
According to our system of comparison, CSBR is a better buy in the short-term than MREO.

Price Growth

CSBR (@Biotechnology) experienced а -12.46% price change this week, while MREO (@Biotechnology) price change was -40.48% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.06%. For the same industry, the average monthly price growth was +13.69%, and the average quarterly price growth was +40.92%.

Reported Earning Dates

CSBR is expected to report earnings on Sep 10, 2025.

MREO is expected to report earnings on Nov 18, 2025.

Industries' Descriptions

@Biotechnology (+2.06% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MREO($278M) has a higher market cap than CSBR($116M). CSBR YTD gains are higher at: -2.450 vs. MREO (-50.000). CSBR has higher annual earnings (EBITDA): 8.43M vs. MREO (-44.87M). MREO has more cash in the bank: 62.5M vs. CSBR (3.2M). MREO has less debt than CSBR: MREO (747K) vs CSBR (6.44M). CSBR has higher revenues than MREO: CSBR (58.6M) vs MREO (0).
CSBRMREOCSBR / MREO
Capitalization116M278M42%
EBITDA8.43M-44.87M-19%
Gain YTD-2.450-50.0005%
P/E Ratio18.58N/A-
Revenue58.6M0-
Total Cash3.2M62.5M5%
Total Debt6.44M747K862%
FUNDAMENTALS RATINGS
CSBR vs MREO: Fundamental Ratings
CSBR
MREO
OUTLOOK RATING
1..100
575
VALUATION
overvalued / fair valued / undervalued
1..100
83
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
1098
PRICE GROWTH RATING
1..100
5294
P/E GROWTH RATING
1..100
672
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MREO's Valuation (72) in the null industry is in the same range as CSBR (83) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

MREO's Profit vs Risk Rating (100) in the null industry is in the same range as CSBR (100) in the Biotechnology industry. This means that MREO’s stock grew similarly to CSBR’s over the last 12 months.

CSBR's SMR Rating (10) in the Biotechnology industry is significantly better than the same rating for MREO (98) in the null industry. This means that CSBR’s stock grew significantly faster than MREO’s over the last 12 months.

CSBR's Price Growth Rating (52) in the Biotechnology industry is somewhat better than the same rating for MREO (94) in the null industry. This means that CSBR’s stock grew somewhat faster than MREO’s over the last 12 months.

MREO's P/E Growth Rating (2) in the null industry is somewhat better than the same rating for CSBR (67) in the Biotechnology industry. This means that MREO’s stock grew somewhat faster than CSBR’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CSBRMREO
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 2 days ago
86%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 1 day ago
67%
Bearish Trend 2 days ago
82%
MACD
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 2 days ago
87%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 2 days ago
88%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
74%
Bearish Trend 2 days ago
87%
Advances
ODDS (%)
Bullish Trend about 1 month ago
73%
Bullish Trend 16 days ago
80%
Declines
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 7 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 2 days ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
71%
Bullish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CSBR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MREO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
AMADF83.201.70
+2.08%
Amadeus IT Group SA
QURT0.60N/A
N/A
Quarta-Rad, Inc.
LEAT9.28-0.05
-0.54%
Leatt Corp.
YLLXF6.55-0.08
-1.21%
Yellow Cake Plc
DCCPF62.38-2.62
-4.03%
DCC Plc

CSBR and

Correlation & Price change

A.I.dvisor tells us that CSBR and SYRE have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CSBR and SYRE's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CSBR
1D Price
Change %
CSBR100%
+7.18%
SYRE - CSBR
32%
Poorly correlated
+4.26%
SCNI - CSBR
27%
Poorly correlated
-0.77%
OABI - CSBR
25%
Poorly correlated
-1.01%
MREO - CSBR
24%
Poorly correlated
+4.09%
PLUR - CSBR
24%
Poorly correlated
+5.15%
More

MREO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MREO has been loosely correlated with RARE. These tickers have moved in lockstep 66% of the time. This A.I.-generated data suggests there is some statistical probability that if MREO jumps, then RARE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MREO
1D Price
Change %
MREO100%
+2.34%
RARE - MREO
66%
Loosely correlated
+0.40%
TRDA - MREO
47%
Loosely correlated
+0.16%
CGON - MREO
43%
Loosely correlated
+4.53%
TERN - MREO
41%
Loosely correlated
+4.36%
NRIX - MREO
40%
Loosely correlated
+2.22%
More